Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 2019; 380: 711-719.

Published: 29th April 2019

Authors: Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A et al.

Conclusion

Patients starting chemotherapy who were at intermediate or high risk of venous thromboembolism (VTE) were included. Apixaban reduced the VTE rate from 10.2 to 4.2 per cent (P<0.001) in this study of 563 patients.

Pubmed Link

Your comments

0 Comments